TCL Archive DRCCA Board Votes To Pull NCI Out Of Joint Program With OSHA For Workplace Education And Prevention January 29, 1982
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004